Visual function loss from vigabatrin: Effect of stopping the drug

Neurology

Volumn 55, Issue 1, 2000, Pages 40-45

  Johnson, Mary A ^a,c   Krauss, G L ^b   Miller, N R ^b   Medura, M ^b   Paul, S R ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIGABATRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION FUNCTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; ELECTRORETINOGRAM; EPILEPSY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

EID: 0034641270     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.1.40     Document Type: Article

References (21)

1. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:614-618.
2. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999;106:1792-1798.
3. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin for intractable seizures: clinical and electrophysiologic findings. Neurology 1999;53:2082-2087.
4. Sills GJ, Patsalos PN, Butler E, Forrest G, Ratnaraj N, Brodie MJ. Concentration-related pharmacodynamic studies with vigabatrin and tiagabine in rat brain and eye. Epilepsia 1999; 40:132. Abstract.
5. Euler T, Wassle H. Different contribution of GABA(A) and GABA(C) receptors to rod and cone bipolar cells in the rat retinal slice. Invest Ophthalmol Vis Sci 1998;39:S980. Abstract.
6. Martinez C, Noack H. The risk of visual field defects and the use of vigabatrin. Kansas City, MO: Hoechst Marion Roussel, 1991.
7. Kalviainen R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53:922-926.
8. Diabetic Retinopathy Study Group. Diabetic Retinopathy Study. Manual of operations. Baltimore, MD: Diabetic Retinopathy Study Coordinating Center, 1972.
9. Hood DC, Birch DG. Light adaptation of human rod receptors: the leading edge of human a-wave and models of rod receptor activity. Vision Res 1993;33:1605-1618.
10. Severns ML, Johnson MA, Merritt SA. Automated estimation of latency and amplitude from the flicker electroretinogram. Appl Optics 1991;30:2106-2112.
11. Severns ML, Johnson MA, Bresnick GH. Methodological dependence of electroretinogram oscillatory potential amplitudes. Doc Ophthalmol 1994;86:23-31.
12. Sutter EE, Tran D. The field topography of ERG components in man: 1. The photopic luminance response. Vision Res 1992; 32:433-466.
13. Severns ML, Johnson MA. Variability of the b-wave of the human ERG with intensity. Doc Ophthalmol 1993;84:291-299.
14. Versino M, Veggiotti P. Reversibility of vigabatrin-induced visual-field defect. Lancet 1999;354:486.
15. Valdizan EM, Garcia AP, Armijo JA. Time course of the GABAergic effects of vigabatrin: is the time course of brain GABA related to platelet GABA-transaminase inhibition? Epilepsia 1999;40:1062-1069.
16. Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999;52:1201-1205.
17. Peterson WM, Miller SS. Identification and functional characterization of a dual GABA/taurine transporter in the bullfrog retinal pigment pigment epithelium. J Gen Physiol 1995;106: 1089-1122.
18. Pourcho RG. Update of tritiated glycine and tritiated GABA by amacrine cells in the cat retina. Brain Res 1990;198:333-346.
19. Haesendonck EC, Missotten L. A subgroup of bipolar cells in human retina is GABA-immunoreactive. Neurosci Lett 1993; 161:187-190.
20. Mackenzie R, Klistorner A. Asymptomatic as well as symptomatic defects occur with vigabatrin. BMJ 1998;316:233. Letter.
21. Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999;67:716-722.